PL2433637T3 - Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych - Google Patents

Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych

Info

Publication number
PL2433637T3
PL2433637T3 PL10732398T PL10732398T PL2433637T3 PL 2433637 T3 PL2433637 T3 PL 2433637T3 PL 10732398 T PL10732398 T PL 10732398T PL 10732398 T PL10732398 T PL 10732398T PL 2433637 T3 PL2433637 T3 PL 2433637T3
Authority
PL
Poland
Prior art keywords
neurodegenerative diseases
quinazoline derivatives
quinazoline
derivatives
neurodegenerative
Prior art date
Application number
PL10732398T
Other languages
English (en)
Inventor
Gil Ana Martínez
Ayuso-Gontan Carmen Gil
Martín Concepción Pérez
Castillo Ana Pérez
García José Morales
Sancho Miriam Redondo
San Cristóbal Marina Sanz
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of PL2433637T3 publication Critical patent/PL2433637T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10732398T 2009-05-20 2010-05-20 Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych PL2433637T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200930189A ES2353093B1 (es) 2009-05-20 2009-05-20 Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
EP10732398.2A EP2433637B9 (en) 2009-05-20 2010-05-20 Use of quinazoline derivatives for neurodegenerative diseases
PCT/ES2010/070338 WO2010133742A1 (es) 2009-05-20 2010-05-20 Uso de derivados de quinazolinas en enfermedades neurodegenerativas

Publications (1)

Publication Number Publication Date
PL2433637T3 true PL2433637T3 (pl) 2014-12-31

Family

ID=42732572

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10732398T PL2433637T3 (pl) 2009-05-20 2010-05-20 Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych

Country Status (10)

Country Link
US (1) US9192610B2 (pl)
EP (1) EP2433637B9 (pl)
JP (1) JP5563068B2 (pl)
AU (1) AU2010251044B2 (pl)
DK (1) DK2433637T5 (pl)
ES (2) ES2353093B1 (pl)
PL (1) PL2433637T3 (pl)
PT (1) PT2433637E (pl)
SI (1) SI2433637T1 (pl)
WO (1) WO2010133742A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
ES2544519B1 (es) 2015-05-22 2016-03-04 Consejo Superior De Investigaciones Científicas (Csic) Quinazolinas S-sustituidas y sus aplicaciones terapéuticas para el tratamiento de enfermedades mediadas por PDE7
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
WO2017062500A2 (en) * 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017069173A1 (ja) * 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
EP4028013A4 (en) 2019-09-12 2023-10-18 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
CN119768172A (zh) 2022-08-18 2025-04-04 米托迪治愈有限责任公司 具有磷酸二酯酶-7抑制活性的治疗剂在治疗和预防与慢性疲劳、衰竭和/或劳累不耐受有关的疾病中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
ES2308916B1 (es) * 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7

Also Published As

Publication number Publication date
US9192610B2 (en) 2015-11-24
ES2498828T3 (es) 2014-09-25
EP2433637A1 (en) 2012-03-28
PT2433637E (pt) 2014-09-09
WO2010133742A1 (es) 2010-11-25
EP2433637B1 (en) 2014-06-11
AU2010251044A1 (en) 2012-03-01
ES2353093B1 (es) 2012-01-03
DK2433637T3 (en) 2014-08-18
DK2433637T5 (da) 2015-08-31
SI2433637T1 (sl) 2014-09-30
EP2433637B9 (en) 2015-06-10
ES2353093A1 (es) 2011-02-25
JP2012527434A (ja) 2012-11-08
JP5563068B2 (ja) 2014-07-30
AU2010251044B2 (en) 2014-08-28
US20120129877A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
IL219073A (en) A drug combination for cancer treatment
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HUE072183T2 (hu) Génterápia neurodegeneratív betegségekre
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
IL221132A0 (en) Derivatives of betulin
EP2417448A4 (en) BIOMARKERS FOR MONITORING THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES
ZA201301601B (en) Treatment of diseases
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
PL2433637T3 (pl) Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych
EP2414824A4 (en) BIOMARKERS FOR MONITORING THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES
ZA201106294B (en) Treatment of dyskinesia related disorders
IL215368A0 (en) Therapeutic uses of quinazolinedione derivatives
IL207046A (en) Quinazoline derivatives for the treatment of cancer-related disorders
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
GB2468936B (en) Chlorination of sucrose-6-esters
ZA201302390B (en) Arylosulfonamides for the treatment of cns diseases
IL219872A0 (en) Quinazoline derivatives
IL225624A0 (en) Treatment with porphyrin in neurodegenerative diseases
GB201012926D0 (en) Compounds for treatment of inflammation
WO2010083208A9 (en) Treating neuropsychiatric diseases
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
GB0906026D0 (en) Therapeutic compounds